Woodstock (Atlanta), GA
On May 2, 2019, DoseLogix filed suit against BiosRx, Inc. in the United States District Court for the Eastern District of California for infringement of DoseLogix’s U.S. Patent 10,086,146. The suit (Case No. 2:19-cv-00777) seeks to enjoin and recover damages for BiosRx, Inc.’s misappropriation of DoseLogix’s patented technology through the sale of BiosRx, Inc.’s Gentle Dose® Vaginal Applicator and TICKER® Unlimited products.
DoseLogix has been a pacesetter in the healthcare industry since the introduction of the popular Topi-CLICK® topical dosing applicator in 2007. The accuracy, innovative design, and ease-of-use of the Topi-CLICK® has created brand loyalty among compounding pharmacists, physicians, and patients, and has also been recognized through numerous patent grants. DoseLogix’s innovations extend to additional DoseLogix products as well, including the revolutionary Topi-CLICK® Perl™ Vaginal Dosing Applicator.
“As an innovator in the industry, DoseLogix has developed a wide range of dosing applicators that serve patients in the human and veterinary markets. We know that medication accuracy and ease-of-use are important to patients, physicians, and pharmacists so we continue to invest in creating the most advanced technology on the market. Obtaining patents for our products help protect these technological advancements that we’ve invented over the years and if needed, we will take action to protect our company’s technology,” said Tim Phipps, president of DoseLogix.
DoseLogix, based in Woodstock (Atlanta), GA., manufactures a variety of products to support its flagship brand, Topi-CLICK®, including the Topi-CLICK® 35, the larger volume Topi-CLICK® 140, the revolutionary Topi-CLICK® Perl™ Vaginal Dosing Applicator, and the new micro-dosing Topi-CLICK Micro®. For further information on our products, please visit www.DoseLogix.com, call 1.800.870.8448, or email info@DoseLogix.com.